News

Eli Lilly and Company (NYSE:LLY) is one of the 13 Best Low Risk High Growth Stocks to Buy. Amid carrying on new studies, the ...
Eli Lilly (LLY) made headlines with positive results from the Phase 3 BRUIN CLL-314 clinical trial for Jaypirca, marking a significant advancement in treatment options for chronic lymphocytic leukemia ...
Eli Lilly and Company (LLY) said on Tuesday that it would acquire California-based private biotechnology company SiteOne Therapeutics, Inc. for up to $1 billion in cash. The $1 billion is ...
Eli Lilly has agreed to acquire privately held biopharma company SiteOne Therapeutics, adding a non-opioid-based pain treatment to the big pharma’s pipeline. The sale agreement will see Eli ...
Eli Lilly outpaces Novo in the GLP-1 market with Tirzepatide and emerging blockbusters, signaling future growth. Read more on ...
Eli Lilly ( LLY 0.64%) has been one of the best-performing pharmaceutical leaders in the past five years. Thanks to strong ...
Eli Lilly LLY recently announced that it has entered into a definitive agreement to acquire the privately held clinical-stage company SiteOne Therapeutics in a deal valued at $1 billion.
We came across a bullish thesis on Eli Lilly and Company on Stock Analysis Compilation’s Substack. In this article, we will ...
Eli Lilly LLY 1.34% agreed to acquire Verve Therapeutics VERV -0.37% for about $1 billion upfront, adding a potential treatment for cardiovascular disease to its portfolio. Under the agreement ...
On May 16, Eli Lilly and Company (NYSE:LLY) announced a partnership with Rznomics to develop RNA-based gene therapies for sensorineural hearing loss, with milestone payments exceeding $1.3 billion.
Eli Lilly (NYSE:LLY) is a pharmaceutical titan with an $815 billion market cap, putting it on track to be the next $1 trillion stock and the first healthcare company to do so. Trading at $852 per ...
Eli Lilly is further expanding its RNA medicine strategy by tapping South Korea’s Rznomics for a $1.3 billion biobucks deal focused on treating hearing loss. The centerpiece of the agreement is ...